Nyrada Inc Annual Report 2020

NYRADA INC (ASX:NYR) 8 Directors’ Report The directors of Nyrada Inc. (“Nyrada” or “the Company”) submit herewith the financial report of the Company and its wholly owned subsidiaries (“Group or Consolidated Entity”) for the financial year ended 30 June 2020 as follows: Information about the directors The names and particulars of the directors of the Group during or since the end of the financial year are: John Moore Non-executive Chairman, joined the Board on 4 th of June 2019. John currently serves as Chairman of Trialogics a clinical trial informatics business. John was CEO of Acorn Energy from 2006 to 2015 during which time the CoaLogix business was acquired for $11 million and sold for $101 million and the Comverge business listed in the US before its sale to Constellation Energy. In 2002 he was a partner and CEO of Edson Moore Healthcare Ventures and acquired for $148 million a portfolio of sixteen drug delivery investments from Elan Pharmaceuticals. John is a director of Scientific Industries (SCND-OTCQX) a producer of laboratory instruments for the life sciences industry. He is a graduate of Rutgers University, US. Dr Graham Kelly Ph.D Founder and Non-executive Director, joined the Board in August 2017. Graham Kelly is a scientist with 50 years’ experience in drug development in both academic and biotechnology sectors. Graham is the Founder and Executive Chairman of Noxopharm Limited (ASX:NOX), a major shareholder of Nyrada. Graham has also founded two public, listed drug development companies (Novogen Limited, Marshall Edwards Inc), serving variously as Managing Director and Executive Chairman of those companies. Graham holds a PhD from The University of Sydney, and degrees in Science and Veterinary Science from The University of Sydney. Peter Marks Non-executive Director, joined the Board in August 2017 Peter Marks has over 30 years’ experience in corporate advisory, investment banking and director/advisory roles to the Board. Peter is currently a Director of Alterity Therapeutics Limited (ASX:ATH and NASDAQ:ATHE), Non-Executive Director of Noxopharm Limited (ASX: NOX) and Non-Executive Director of Elsight Ltd (ASX:ELS). Until 31 March, 2020 he was also a Non-Executive Director of Fluence Corporation Ltd (ASX: FLC). Peter holds an MBA from the University of Edinburgh, Scotland, a Bachelor of Economics, Bachelor of Laws and a Graduate Diploma in Commercial Law from Monash University, Australia. Christopher Cox Non-executive Director, joined the Board on 7 November 2019. Christopher Cox has been a partner at Cadwalader, Wickersham & Taft LLP in New York since January 2012. Previously the Chairman of Cadwalader’s Corporate Department and a member of its Management Committee, Chris advises clients on a wide array of corporate and financial matters, including mergers and acquisitions and restructurings, spin-offs, joint ventures, IP monetizations and other complex financing transactions. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy. Prior to January 2012, Chris was a partner at Cahill Gordon & Reindel LLP in New York. Chris also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private investment holding company with interests in biotechnology, network security and entertainment. Chris received both his undergraduate degree and J.D. from the University of Missouri, where he was also a member of the Missouri Law Review.